Lv615
3190 积分 2022-08-26 加入
Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial
1天前
待确认
Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial
1天前
待确认
Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse
1天前
待确认
Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD
8天前
已完结
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia
8天前
已完结
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia
8天前
已完结
Feasibility of Bruton’s Tyrosine Kinase Inhibitor Discontinuation in Chronic Lymphocytic Leukemia: The Patient Perspective
9天前
已关闭
How I use Maintenance Therapy in Acute Myeloid Leukemia
9天前
已完结
How I Treat patients with AML using azacitidine and venetoclax
9天前
已完结
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
12天前
已完结
皖公网安备34019202002308
